Prescribing Update CATHERINE ARMSTRONG – MAY 2014.

Slides:



Advertisements
Similar presentations
Implementing NICE guidance
Advertisements

Prescribing Update CATHERINE ARMSTRONG – NOVEMBER 2014.
Planning, COPD Hot Topics and CSA preparation Ruth Gooch 11/1/12.
Alternative medicines include: Sertraline (optimum alternative as similar indications, low interaction propensity, good tolerability, generic, NICE approved)
The British Approach to Antihypertensive Therapy: Guidelines from the National Institute of Health and Clinical Excellence Power Over Pressure
North of Tyne anti-platelet guidelines: use in primary care Jane S Skinner Consultant Community Cardiologist.
CONSENSUS: Cooperative North Scandinavian Enalapril Survival Study Purpose To determine whether the ACE inhibitor enalapril reduces mortality in patients.
COPD Research at the University of Maryland School of Maryland COPD Clinical Research Center A member of the National Heart Lung & Blood Institute National.
CAPRIE: Clopidogrel versus Aspirin in Patients at risk of Ischemic Events Purpose To assess the relative efficacy of the antiplatelet drugs clopidogrel.
Global Initiative for Asthma (GINA) What’s new in GINA 2015?
Guidelines for Pain Management Paula Wilkinson Chief Pharmacist NHS Mid-Essex.
“URINARY INCONTINENCE IN WOMEN 2013” NICE guidelines implementation in Primary Care Tony Smith Urogynaecologist St Mary’s HospitalAnson Medical CentreManchester.
1 British Guideline on the Management of Asthma BTS/SIGN British Guideline on the Management of Asthma, May 2008 Introduction Diagnosis Non-pharmacological.
Pharmacological Treatment of Hypertension Update 2012.
Afrezza® – inhaled human insulin
Assessment, Targets, Thresholds and Treatment Bryan Williams NICE clinical guideline 127.
Paediatric Prescribing and Common Medications Diana Mowbray Paediatric Clinical Pharmacist Rotherham NHS Foundation Trust.
Asthma Management Fine Tuning  Maximum control with minimum medication  Start with mild asthma and work up the scale (BTS/SIGN 2004)
Karen Homan NHS Bedfordshire
European guidelines on the management of stable coronary artery disease Key points & new position for Ivabradine and Trimetazidine ESC 2013 Montalescot.
Pain management for AKT NICE guidelines: Neuropathic pain Opioid conversion Controlled drugs.
Prescribing Update Catherine Armstrong Lead Pharmacist - Pharmicus.
Anticholinergics in COPD presented by: Soha Ragab Moselhy group 2.
Resources Update January 2014 Christopher Jones Pharmacist.
Medicines management update Catherine Butler Medicines Management Pharmacist.
Medicine used in the Treatment of Obesity
Clopidogrel Audit Vikas Jasoria December What is it? Clopidogrel is a thienopyridine antiplatelet drug which reduces platelet aggregation by inhibiting.
AIRE: Acute Infarction Ramipril Efficacy study Purpose To determine whether the ACE inhibitor ramipril reduces mortality in patients with evidence of heart.
April 09 – September 09  10,245 daily newsletter recipients  18,798,938 pages accessed by users  3,565,340 news items read by users  38,039 records.
Katy Trinkley, PharmDAngie Thompson, PharmD.  Opioid risks and risk prevention strategies  Medication treatment by pain type  Fundamental principles.
SABA (short acting beta agonist) inhalers Aerosol InhalersGeneric Component No of doses Cost/ device Dosing directions Ventolin evohalerSalbutamol 100mcg/dose200£
Question 1 Pozen estimated an annual incidence of tardive dyskinesia (TD) of up to 0.038% for metoclopramide at a daily dose of mg/day for 72 days/year.
Responsible Respiratory Prescribing
Severe breathlessness
Component 4 Medications. Key Points - Medications  2 general classes: – Long-term control medications – Quick-Relief medications  Controller medications:
Long-Term Tolerability of Ticagrelor for Secondary Prevention: Insights from PEGASUS-TIMI 54 Trial Marc P. Bonaca, MD, MPH on behalf of the PEGASUS-TIMI.
Asthma Guidelines, Diagnosis and Management Alison Hughes Respiratory Specialist Nurse Solent NHS Trust.
Wendy Pigg Practice support Pharmacist/Independent Prescriber
East & South East England Specialist Pharmacy Services East of England, London, South Central & South East Coast NSAIDS – Efficacy and Safety Expert speaker.
Lancet Respir Med 2013; 1: 199–209 R4.신재령 / Prof. 박명재
내과 R2 이지훈 N Engl J Med Sep 8.
New Therapies for Asthma & COPD
Prescribing in cardiovascular disease By Jole Hannan Medicines Optimisation Pharmacist.
Prescribing for patients with COPD Evidence Update Emma Blanden- Pharmacist.
Pain Ladder and Opiate Conversion Christopher Haigh Medicines Optimisation Pharmacist Bolton CCG.
Lynn Helliwell.
Management of stable chronic obstructive pulmonary disease (2) Seminar Training Primary Care Asthma + COPD D.Anan Esmail.
Telmisartan Hydrochlorothiazide Price Buy Microzide Online xenia hydrochlorothiazide hydrochlorothiazide for vertigo hydrochlorothiazide innovator can.
NHS Specialist Pharmacy Service NSAIDS – efficacy and safety Expert speaker Slide set Key content from the NPC NSAIDS QIPP slides is gratefully acknowledged.
Clinical Knowledge Summaries CKS Analgesia – mild to moderate pain Prescribing analgesics for mild to moderate pain in adults and children. Educational.
New inhalers for COPD and asthma 2015
Specials November Update
Medicines Optimisation
Nuplazid™ - Pimavanserin
Efficacy and safety of once-daily QVA149 compared with twice-daily salmeterol–fluticasone in patients with chronic obstructive pulmonary disease (ILLUMINATE):
Monitoring asthma in primary care
Summary and Next Steps Linda Lord – Chief Pharmacist
The Role of Anticholinergic Therapy in Moderate to Severe Asthma
Menopause Update Dr Fiona Jacklin April 2018
Medicines Optimisation
Dual Bronchodilation in COPD: From Clinical Trial Evidence to Clinical Practice.
What Is the Role of Dual LAMA/LABA Bronchodilation in COPD Therapy in Light of New Clinical Data?
Table of Contents Why Do We Treat Hypertension? Recommendation 5
Pharmacological Treatment of Hypertension Update 2012
Prescribing Update - Respiratory July 2019
Presentation transcript:

Prescribing Update CATHERINE ARMSTRONG – MAY 2014

Summary  Hot topics  New inhalers  NICE guidelines  Drug shortages  Updated BNF distribution schedules

Hot Topic: Domperidone  MHRA Alert – 25 th April  Small increased risk of potentially life-threatening effects on the heart  ONLY for nausea and vomiting  MAX 7 days treatment  ADULT dose – 10mg TDS  Check for QT prolongation meds and CYP3A4 inhibitors  Review patients at next routine appointment

Hot Topic: Strontium  Restricted to severe osteoporosis  …who cannot use any other treatments  Do NOT start in patients who have or had  Ischaemic heart disease  Peripheral arterial disease  Cerebrovascular disease  Uncontrolled hypertension  STOP if develop any of the above

New Inhalers  COPD  Aclidinium bromide  Glycopyrronium bromide  Indacaterol + Glycopyrronium  Asthma  Fluticasone furorate + vilanterol

Aclidinium bromide (Eklira Genuir®)  LAMA – 400micrograms/dose – TWICE daily for COPD  ↑ effect on lung function vs placebo  No robust evidence of benefit vs other LAMA options  Device: multi-dose dry powder inhaler  On some local formularies:  North of Tyne  Gateshead ?  South Tyneside   Sunderland ?  Durham&Darlington

Glycopyrronium bromide (Seebri Breezhaler®)  LAMA – 44micrograms/dose – ONCE daily for COPD  ↑ effect on lung function, exercise endurance & patient outcomes vs placebo  May provide more rapid bronchdilation than tiotropium  Needs long term safety data & direct comparator trials  Device = capsule based dry powder inhaler  On some local formularies:  North of Tyne  Gateshead ?  South Tyneside   Sunderland ?  Durham&Darlington

Indacaterol + Glycopyrronium (Ultibro Breezhaler®  LABA+LAMA 85micrograms indacaterol + 43micrograms glycopyronnium  ONCE daily for COPD  Device = capsule based dry powder inhaler  ↑ lung function vs placebo, separates + fluticasone/salmeterol  ↓ rate of exacerbations compared to glycopyronnium alone  Not considered locally yet

Fluticasone furorate + vilanterol (Relvar®)  ICS+LABA – 2 strengths 92/22 & 184/22micrograms  ONCE daily for asthma  Superior to fluticasone furoate alone  92/22 comparable efficacy to fluticasone/salmeterol 250/50 BD  CONCERNS re product – MHRA review  Not considered locally yet

NICE Guidelines  CG171: Urinary Incontinence in Women  Darifenacin, oxybutynin (IR) & tolteridone (IR) – 1 st line  CG172: Myocardial Infarction – secondary prevention  Omega 3 fatty acids – DO NOT RECOMMEND for 2ndry prevention of MI  CG173: Neuropathic Pain – pharmacological management  Tramadol not for long-term neuropathic pain control  Carbamazepine ONLY for trigeminal neuralgia

Drug Shortages - Valsartan  Intermittent supply problems – all strengths & forms  May last several months * Dose equivalences are approximate and individual responses may vary so BP should be monitored following the switch and dosing adjusted accordingly, if needed #Valsartan doses may be given as 2 divided doses depending on indication Taken from NHS England Memo 10/3/2014: England/Medicines-Information/Discontinuation-Supply-Shortage-Memos/Shortage-of-Valsartan-/ A2RA Approximate dose conversions * Valsartan40mg daily#80mg daily#160mg daily#320mg daily# Candesartan4mg OD8mg OD16mg OD16-32mg OD Losartan25mg OD50mg OD100mg OD

Drug shortages – Piroxicam gel  Some supplies available  NHS prices currenly based on Feldene® gel  60g = £6.00 (was £2.71)  112g = £9.41(was £5.06)  Compared with  Ibuprofen 5% gel £2.11 (50g), £4.22 (100g)  Ibuprofen 10% gel £5.79 (100g)

Drug shortages - various  Clomipramine  Branded product discontinued  Cross-tapering with SSRIs, venlafaxine or duloxetine – specialist use only  Example switch to imipramine:  Gradually reduce to 75mg/day, stop and start imipramine mg/day the next day  Co-amoxiclav  Can be obtained – prices higher than usual  375mg £5.30/21 625mg £6.93/21  Use ONLY where clinically appropriate

Drug shortages – various (2)  Amiloride£19.10 per 28  Co-amilofruse2.5/20 £4.32 per 285/40 £5.29 per 28  Co-tenidone50/12.5 £5.18 per 28100/25 £5.18 per 28  Is a potassium sparing diuretic needed?  Avoid combination products where possible

Drug shortages – various (3)  Mebeverine135mg tablets £17.50 per 100  Peppermint oil 0.2ml caps £7.04 per 84  Propranolol  10mg £5.30 (28)40mg £4.10 (28)80mg £6.44 (56)  Consider alternative beta-blocker  HF – bisoprolol, carvedilol and nebivolol = licensed options

BNF Distribution  From Sept 2013 edition – annually in PRINT  Still updated every 6 months (print copy)  Online/App versions updated monthly  Register for NHS Athens account:  Info regarding print distribution:  ALL GPs should receive annual PRINT copy to place of work 